Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.04
NYSE:BSX's Cash to Debt is ranked lower than
95% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NYSE:BSX: 0.04 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:BSX' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.13 Max: 0.69
Current: 0.04
0.03
0.69
Equity to Asset 0.37
NYSE:BSX's Equity to Asset is ranked lower than
80% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:BSX: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:BSX' s Equity to Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.5 Max: 0.63
Current: 0.37
0.18
0.63
Interest Coverage 0.15
NYSE:BSX's Interest Coverage is ranked lower than
100% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 73.78 vs. NYSE:BSX: 0.15 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BSX' s Interest Coverage Range Over the Past 10 Years
Min: 0.15  Med: 1.8 Max: 3.22
Current: 0.15
0.15
3.22
F-Score: 7
Z-Score: 1.26
M-Score: -2.60
WACC vs ROIC
6.66%
2.41%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 0.44
NYSE:BSX's Operating margin (%) is ranked lower than
53% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NYSE:BSX: 0.44 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:BSX' s Operating margin (%) Range Over the Past 10 Years
Min: -53.36  Med: -6.39 Max: 11.86
Current: 0.44
-53.36
11.86
Net-margin (%) 0.99
NYSE:BSX's Net-margin (%) is ranked lower than
52% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NYSE:BSX: 0.99 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:BSX' s Net-margin (%) Range Over the Past 10 Years
Min: -56.12  Med: -9.22 Max: 5.79
Current: 0.99
-56.12
5.79
ROE (%) 1.27
NYSE:BSX's ROE (%) is ranked higher than
50% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. NYSE:BSX: 1.27 )
Ranked among companies with meaningful ROE (%) only.
NYSE:BSX' s ROE (%) Range Over the Past 10 Years
Min: -44.65  Med: -5.9 Max: 3.89
Current: 1.27
-44.65
3.89
ROA (%) 0.45
NYSE:BSX's ROA (%) is ranked higher than
51% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NYSE:BSX: 0.45 )
Ranked among companies with meaningful ROA (%) only.
NYSE:BSX' s ROA (%) Range Over the Past 10 Years
Min: -21.16  Med: -2.76 Max: 2.03
Current: 0.45
-21.16
2.03
ROC (Joel Greenblatt) (%) -0.77
NYSE:BSX's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NYSE:BSX: -0.77 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:BSX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -153.31  Med: -20.85 Max: 32.39
Current: -0.77
-153.31
32.39
Revenue Growth (3Y)(%) 2.70
NYSE:BSX's Revenue Growth (3Y)(%) is ranked lower than
55% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NYSE:BSX: 2.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:BSX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.5  Med: 2.7 Max: 28.7
Current: 2.7
-10.5
28.7
EPS Growth (3Y)(%) -60.40
NYSE:BSX's EPS Growth (3Y)(%) is ranked lower than
97% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NYSE:BSX: -60.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:BSX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -60.4  Med: 7.2 Max: 62
Current: -60.4
-60.4
62
» NYSE:BSX's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-07-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

BSX Guru Trades in Q4 2015

Jim Simons 3,471,705 sh (New)
Pioneer Investments 3,668,146 sh (+0.80%)
Vanguard Health Care Fund 64,108,690 sh (unchged)
Michael Price 1,980,000 sh (unchged)
Steven Cohen 650,000 sh (unchged)
Samuel Isaly 3,450,000 sh (unchged)
Andreas Halvorsen Sold Out
PRIMECAP Management 43,346,700 sh (-0.60%)
Mario Gabelli 821,746 sh (-2.96%)
Dodge & Cox 450,830 sh (-4.68%)
Diamond Hill Capital 19,599,806 sh (-5.43%)
Ray Dalio 88,284 sh (-14.85%)
Alan Fournier 3,909,834 sh (-19.70%)
Steven Cohen 690,300 sh (-73.84%)
» More
Q1 2016

BSX Guru Trades in Q1 2016

John Paulson 74,000 sh (New)
Steven Cohen 2,665,600 sh (+286.15%)
Diamond Hill Capital 20,339,317 sh (+3.77%)
Pioneer Investments 3,787,109 sh (+3.24%)
PRIMECAP Management 43,354,400 sh (+0.02%)
Samuel Isaly 3,450,000 sh (unchged)
Alan Fournier Sold Out
Vanguard Health Care Fund 63,222,390 sh (-1.38%)
Mario Gabelli 796,046 sh (-3.13%)
Dodge & Cox 427,430 sh (-5.19%)
Michael Price 1,740,000 sh (-12.12%)
Ray Dalio 36,184 sh (-59.01%)
Jim Simons 618,405 sh (-82.19%)
» More
Q2 2016

BSX Guru Trades in Q2 2016

Paul Tudor Jones 33,994 sh (New)
Jim Simons 4,901,905 sh (+692.67%)
John Paulson 94,000 sh (+27.03%)
Samuel Isaly 3,880,000 sh (+12.46%)
PRIMECAP Management 42,640,450 sh (-1.65%)
Dodge & Cox 384,930 sh (-9.94%)
Mario Gabelli 687,746 sh (-13.60%)
Vanguard Health Care Fund 53,619,190 sh (-15.19%)
Pioneer Investments 2,962,863 sh (-21.76%)
Steven Cohen 1,915,982 sh (-28.12%)
Michael Price 900,000 sh (-48.28%)
Ray Dalio 9,684 sh (-73.24%)
Diamond Hill Capital 4,863,821 sh (-76.09%)
» More
Q3 2016

BSX Guru Trades in Q3 2016

Ray Dalio 50,900 sh (+425.61%)
John Paulson 410,000 sh (+336.17%)
Dodge & Cox 382,130 sh (-0.73%)
PRIMECAP Management 41,805,050 sh (-1.96%)
Mario Gabelli 673,046 sh (-2.14%)
Vanguard Health Care Fund 46,520,049 sh (-13.24%)
Steven Cohen 1,622,600 sh (-15.31%)
Paul Tudor Jones 26,610 sh (-21.72%)
Michael Price 700,000 sh (-22.22%)
Diamond Hill Capital 3,289,862 sh (-32.36%)
Pioneer Investments 1,878,761 sh (-36.59%)
Jim Simons 1,884,005 sh (-61.57%)
Samuel Isaly 1,698,025 sh (-56.24%)
» More
» Details

Insider Trades

Latest Guru Trades with BSX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:ISRG, NYSE:STJ, NYSE:ZBH, NYSE:EW, NYSE:SYK, OTCPK:SNNUF, NYSE:VAR, OTCPK:SONVY, NAS:ALGN, NYSE:TFX, OTCPK:CHEOY, NAS:ABMD, OTCPK:EKTAY, NAS:NUVA, NAS:IART, NAS:MASI, NAS:LIVN, NYSE:NVRO, NAS:WMGI, NYSE:PEN » details
Traded in other countries:BSX.Germany,
Boston Scientific Inc is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. The Company's products were offered for sale by seven core businesses - Interventional Cardiology, Cardiac Rhythm Management (CRM), Endoscopy, Peripheral Interventions (PI), Urology and Women's Health, Neuromodulation, and Electrophysiology (EP). market a broad portfolio of internally-developed and self-manufactured drug-eluting stents including the Promus Element and Promus Element Plus everolimus-eluting stents, as well as its TAXUS Element and Ion paclitaxel-eluting stents. The Company sell various products designed to treat patients with peripheral disease (disease which appears in blood vessels other than in the heart and in the biliary tree), including a broad line of medical devices used in percutaneous transluminal angioplasty (PTA) and peripheral vascular stenting. Its peripheral product offerings include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters. Its peripheral angioplasty balloon technology includes its next-generation Mustang PTA balloon, its Coyote balloon catheter, a deliverable and ultra-low profile balloon dilatation catheter designed for a wide range of peripheral angioplasty procedures, and its Charger PTA Balloon Catheter, a 0.035" percutaneous transluminal angioplasty balloon catheter designed for post-stent dilatation as well as conventional balloon angioplasty to open blocked peripheral arteries. The Company also sell products designed to treat patients with non-vascular disease (disease that appears outside the blood system). Its non-vascular suite of products includes biliary stents, drainage catheters and micro-puncture sets designed to treat, diagnose and ease various forms of benign and malignant tumors. The Company continue to market its extensive line of Interventional Oncology product solutions, including the recently launched Renegade HI-FLO Fathom microcatheter and guidewire system and Interlock - 35 Fibered IDC Occlusion System for peripheral embolization. The Company develop, manufacture and market a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, including: Implantable cardioverter defibrillator (ICD), Implantable pacemaker systems. The Company is subject to various environmental laws, directives and regulations both in the U.S. and abroad. Its operations, like those of other medical device companies, involve the use of substances regulated under environmental laws in manufacturing and sterilization processes.

Top Ranked Articles about Boston Scientific Corp

Diamond Hill Buys Ford, Sells Boston Scientific Firm's largest 2nd quarter trades
Diamond Hill Capital (Trades, Portfolio) Management Inc. was established in 2000 and is a registered investment adviser based in Columbus, Ohio. During the second quarter, the firm traded the following stocks. Read more...
Michael Price Trims Boston Scientific, Buys Outerwall The guru's largest trades of 2nd quarter
Michael Price (Trades, Portfolio) is the 271st richest person in the world, according to Forbes. A renowned money manager, he learned finance as a $200-a-week research assistant under Max Heine. The following are his largest trades of the second quarter: Read more...
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Guru exited position in Pfizer in 2nd quarter
Seven of Vanguard Health Care Fund (Trades, Portfolio)’s top 10 second-quarter transactions were divestitures or reductions, including its most noteworthy deal of the quarter. Read more...
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Recent insider sells from company CEOs
According to GuruFocus Insider Data, these are the largest CEO sells during the past week: Gilead Sciences Inc., Boston Scientific Corp., Sonic Corp. and HealthEquity Inc. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 351.36
BSX's P/E(ttm) is ranked lower than
97% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.16 vs. BSX: 351.36 )
Ranked among companies with meaningful P/E(ttm) only.
BSX' s P/E(ttm) Range Over the Past 10 Years
Min: 13.87  Med: 30.15 Max: 404.33
Current: 351.36
13.87
404.33
Forward P/E 16.58
BSX's Forward P/E is ranked higher than
80% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 21.74 vs. BSX: 16.58 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 351.36
BSX's PE(NRI) is ranked lower than
97% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.53 vs. BSX: 351.36 )
Ranked among companies with meaningful PE(NRI) only.
BSX' s PE(NRI) Range Over the Past 10 Years
Min: 13.87  Med: 30.15 Max: 404.33
Current: 351.36
13.87
404.33
P/B 4.41
BSX's P/B is ranked lower than
62% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. BSX: 4.41 )
Ranked among companies with meaningful P/B only.
BSX' s P/B Range Over the Past 10 Years
Min: 0.59  Med: 1.39 Max: 5.3
Current: 4.41
0.59
5.3
P/S 3.49
BSX's P/S is ranked lower than
55% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. BSX: 3.49 )
Ranked among companies with meaningful P/S only.
BSX' s P/S Range Over the Past 10 Years
Min: 1.02  Med: 2.21 Max: 4.13
Current: 3.49
1.02
4.13
PFCF 52.39
BSX's PFCF is ranked lower than
78% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 26.13 vs. BSX: 52.39 )
Ranked among companies with meaningful PFCF only.
BSX' s PFCF Range Over the Past 10 Years
Min: 7.26  Med: 20.44 Max: 220
Current: 52.39
7.26
220
POCF 34.09
BSX's POCF is ranked lower than
75% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 18.20 vs. BSX: 34.09 )
Ranked among companies with meaningful POCF only.
BSX' s POCF Range Over the Past 10 Years
Min: 5.79  Med: 15.76 Max: 62.72
Current: 34.09
5.79
62.72
EV-to-EBITDA 64.36
BSX's EV-to-EBITDA is ranked lower than
88% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. BSX: 64.36 )
Ranked among companies with meaningful EV-to-EBITDA only.
BSX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -680.1  Med: 8.45 Max: 241.8
Current: 64.36
-680.1
241.8
Current Ratio 1.05
BSX's Current Ratio is ranked lower than
86% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. BSX: 1.05 )
Ranked among companies with meaningful Current Ratio only.
BSX' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.5 Max: 3.46
Current: 1.05
0.52
3.46
Quick Ratio 0.72
BSX's Quick Ratio is ranked lower than
86% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. BSX: 0.72 )
Ranked among companies with meaningful Quick Ratio only.
BSX' s Quick Ratio Range Over the Past 10 Years
Min: 0.33  Med: 1.15 Max: 2.2
Current: 0.72
0.33
2.2
Days Inventory 156.59
BSX's Days Inventory is ranked lower than
59% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. BSX: 156.59 )
Ranked among companies with meaningful Days Inventory only.
BSX' s Days Inventory Range Over the Past 10 Years
Min: 95.18  Med: 125.3 Max: 164.78
Current: 156.59
95.18
164.78
Days Sales Outstanding 61.85
BSX's Days Sales Outstanding is ranked higher than
58% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. BSX: 61.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
BSX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.51  Med: 61.98 Max: 66.79
Current: 61.85
58.51
66.79
Days Payable 45.72
BSX's Days Payable is ranked lower than
59% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. BSX: 45.72 )
Ranked among companies with meaningful Days Payable only.
BSX' s Days Payable Range Over the Past 10 Years
Min: 21.66  Med: 35.22 Max: 340.03
Current: 45.72
21.66
340.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.20
BSX's 3-Year Average Share Buyback Ratio is ranked higher than
82% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. BSX: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BSX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22.3  Med: -0.7 Max: 4.6
Current: 0.2
-22.3
4.6

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.28
BSX's Price/Projected FCF is ranked lower than
58% of the 124 Companies
in the Global Medical Devices industry.

( Industry Median: 1.97 vs. BSX: 2.28 )
Ranked among companies with meaningful Price/Projected FCF only.
BSX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.44 Max: 5.76
Current: 2.28
0.52
5.76
Price/Median PS Value 1.57
BSX's Price/Median PS Value is ranked lower than
81% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. BSX: 1.57 )
Ranked among companies with meaningful Price/Median PS Value only.
BSX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.4 Max: 4.29
Current: 1.57
0.48
4.29
Price/Peter Lynch Fair Value 1.17
BSX's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 47 Companies
in the Global Medical Devices industry.

( Industry Median: 1.58 vs. BSX: 1.17 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BSX' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 1.49 Max: 4.5
Current: 1.17
0
4.5
Forward Rate of Return (Yacktman) (%) 42.98
BSX's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 9.23 vs. BSX: 42.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BSX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.1  Med: 7 Max: 43
Current: 42.98
3.1
43

More Statistics

Revenue (TTM) (Mil) $8,173
EPS (TTM) $ 0.06
Beta0.69
Short Percentage of Float1.63%
52-Week Range $15.67 - 24.79
Shares Outstanding (Mil)1,361.68

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 8,350 8,865 9,460
EPS ($) 1.06 1.21 1.39
EPS w/o NRI ($) 1.06 1.21 1.39
EPS Growth Rate
(3Y to 5Y Estimate)
16.70%
Dividends Per Share ($)
» More Articles for BSX

Headlines

Articles On GuruFocus.com
Medtronic Misses 2nd Quarter Revenue Expectations Nov 27 2016 
Michael Price Sells Dolby Labs, EMC Nov 21 2016 
Vanguard Health Care Fund Sells Amgen, Baxter Nov 02 2016 
Michael Price Trims Boston Scientific, Buys Outerwall Aug 23 2016 
Eaton Vance Worldwide Health Sciences Fund 2nd Quarter Commentary Aug 04 2016 
Vanguard Sold Shares in 7 of Top 10 Quarterly Transactions Aug 02 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Johnson & Johnson Reports 4% Sales Growth for the Second Quarter Jul 22 2016 
Weekly CEO Sells Highlight: Gilead Sciences, Boston Scientific, Sonic, HealthEquity Apr 10 2016 
Weekly CEO Sells Highlight: Motorcar Parts of America, The Interpublic Group of Companies, Gilead Sc Mar 07 2016 

More From Other Websites
Edwards Heart-Valve Guidance Lags On Medtronic, Boston Rivalry Dec 08 2016
Boston Scientific Corporation -- Moody's upgrades Boston Scientific's senior unsecured rating to... Dec 07 2016
Edwards 2017 Guidance Likely Hinges On Rivalry With Medtronic, Boston Dec 06 2016
Boston Scientific (BSX) Inks $75 Million Deal with Neovasc Dec 05 2016
Barclays PLC (ADR) (BCS): Are Hedge Funds Right About This Stock? Dec 04 2016
Boston Scientific Acquisition Eyes Rivals Edwards, Medtronic Dec 02 2016
Boston Scientific Acquisition Eyes Rivals Edwards, Medtronic Dec 02 2016
Boston Scientific Completes Its Acquisition of EndoChoice Dec 02 2016
Neovasc and Boston Scientific Reach US$75 Million Agreement Dec 02 2016
Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities Dec 02 2016
Trial Data Affirms Positive Results of HeartLogic Diagnostic Service Dec 01 2016
Nevro Lawsuit against BSX Could Impact Its Neuromodulation Revenues Dec 01 2016
In Focus: Boston Scientific’s Stock Performance Dec 01 2016
What Do Analysts Recommend for Boston Scientific? Nov 30 2016
Boston Scientific Hit With Patent Lawsuit (BSX, NVRO) Nov 29 2016
Nevro Files Lawsuit for Patent Infringement Against Boston Scientific in the U.S. Nov 28 2016
Boston Scientific Corporation (BSX): Are Hedge Funds Right about This Stock? Nov 28 2016
Boston Scientific To Participate In Citi 2016 Global Healthcare Conference Nov 23 2016
BOSTON SCIENTIFIC CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Nov 22 2016
As Medtronic Shares Plunge, This Analyst Says Buy On Weakness Nov 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)